Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 6 days agoIt will be historic when it is no longer the first prescribed agent in HER2+ mBC and Enhertu may...
UCLA oncologist Dr. Dennis Slamon awarded Szent-Gy | Newswise
Newswise· 4 days agoDr. Dennis Slamon, a world-renowned oncologist and scientist whose groundbreaking research has...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 6 days agoEvorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 5 days agoARX788 is attempting to enter a crowded field, Enhertu (trastuzumab deruxtecan) is the standard of...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via AOL· 6 days ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoA New Top Biotech Stock Corcept Therapeutics is a newer addition to the list of leading biotech...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 4 days agoIn 2024, Teva expects Uzedy sales of approximately $80 million. Teva markets biosimilar versions of...
Top Analyst Reports for Roche, Wells Fargo & GE Aerospace
Zacks via Yahoo Finance· 4 days agoToday's Research Daily features new research reports on 16 major stocks, including Roche Holding AG...